Browse Prior Art Database

Nitrous oxide for the treatment of dyskinesias

IP.com Disclosure Number: IPCOM000238867D
Publication Date: 2014-Sep-23
Document File: 1 page(s) / 56K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a Microsoft Word document.
This is the abbreviated version, containing approximately 59% of the total text.

Nitrous oxide for the treatment of dyskinesias

Dyskinesias are abnormal involuntary movement disorders.

Knowledge of the pathophysiological mechanisms that underlie some of these disorders makes it likely that similar mechanisms mediate disorders characterised by either hyperkinesias or dyskinesias. It is to be expected, therefore, that treatments that are effective in one form of dyskinesia may be beneficial in dyskinesias of different aetiology.

One common way in which dyskinesias arise is as a side-effect of dopamine replacement therapy for parkinsonism or other basal ganglia-related movement disorders (Molecular mechanisms of L-DOPA-induced dyskinesia, Peter J., Nature Reviews Neuroscience, 2008).

Another common cause of dyskinesias is the treatment of psychosis with neuroleptic drugs-this is known as tardive dyskinesia.

Dyskinesia also occurs in many other conditions including: Huntington's disease, idiopathic dystonia,Tourette syndrome, "off" dystonia in parkinsonism, ballism, senile chorea. Many attempts have been made to develop agents that will prevent the development of, and/or treat, dyskinesias although such attempts have met with limited success.

There is, therefore, a need to develop ways by which dyskinesias may be treated.

One strategy could be to use N-methyl-D-aspartate (NMDA) receptor antagonists to treat dyskinesias. (Novel pharmacological targets for the treatment of Parkinson’s disease, Schapira A. et al., Nature reviews drugs discovery, 2006).

Indeed...